Thomas Grothier

This paper develops ENTPD3-specific CAR Tregs to control T1D by targeting beta cells and shows their efficacy in preventing disease progression in a mouse model.

This paper introduces a dimerization domain from IgG1 antibodies to create engineered cytokine receptors that mimic natural heterodimerization, enhancing CAR T cell therapy efficacy.

This study investigates the role of SHP1 and SHP2 in T-cell immunosuppression by expressing truncated variants and shows that dSHP2 can alleviate PD1-mediated suppression in CAR T cells.